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Abstract 
As pediatric biobank research grows, additional guidance will be needed about whether 
researchers should always obtain consent from participants when they reach the legal age of 
majority. Biobanks struggle with a range of practical and ethical issues related to this issue. 
We propose a framework for the use of “anticipatory waivers of consent,” which is empirically 
rooted in research that shows children and adolescents are often developmentally capable of 
meaningful deliberation about the risks and benefits of participation in research. Accordingly, 
bright line legal concepts of majority or competency do not accurately capture the emerging 
capacity for autonomous decision-making of many pediatric research participants and 
unnecessarily complicate the issues about contacting participants at the age of majority to obtain 
consent for the continued or first use of their biospecimens that were obtained during childhood. 
We believe the proposed framework provides an ethically sound balance between the concern for 
potential exploitation of vulnerable populations, the impetus for the federal regulations 
governing research with children, and the need to conduct valuable research in the age of 
genomic medicine. 
Keywords:  Biobanking, pediatric biobank participants, consent at age of majority, 
institutional review boards, anticipatory waiver of consent 
The completion of the Human Genome Project in 2003 has led to a significant increase in the 
number of biobanks storing human biospecimens. Research by Henderson, et al. in 2013 
revealed nearly 900 biobanks operating in the United States1 – a number that has certainly grown 
in the five years since their study – with the majority of biobanks engaged in genetic research.2  
Nearly 50% of these biobanks each contain more than 10,000 individual biospecimens and 44% 
contain at least some biospecimens collected from individuals under the age of 18.3  Moreover, 
nearly half of biobanks identify their main biospecimens as “DNA”.4  This changing research 
landscape presents particular challenges in the pediatric context. At issue is whether researchers 
should obtain consent from pediatric biobank participants when they reach the legal age of 
consent for the first or ongoing use of their biospecimens.  
Subpart D of the federal regulations governing research with humans, which describes 
the requirements for protections for research with children, is silent on the issue about obtaining 
consent from pediatric biobank participants when they reach the age of majority.5 The only 
specific guidance on this issue comes from the Office for Human Research Protections (OHRP) 
in the Frequently Asked Questions (FAQ) section of its Web site: 
When a child who was enrolled in research with parental or guardian permission 
subsequently reaches the legal age of consent to the procedures involved in 
ongoing research, the subject’s participation in the research is no longer regulated 
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by the requirements of 45 CFR part 46.408 regarding parental or guardian 
permission and subject assent. 
 
Unless the Institutional Review Board (IRB) determines that the requirements for 
obtaining informed consent can be waived, the investigators should seek and 
obtain the legally effective informed consent, as described in 45 CFR 46.116, for 
the now-adult subject for any ongoing interactions or interventions with the 
subjects. This is because the prior parental permission and child assent are not 
equivalent to legally effective informed consent for the now-adult subject. 
However, the IRB could approve a waiver of informed consent under 45 CFR 
46.116(d), if the IRB finds and documents that the required conditions are met. 
 
Similarly, if the research does not involve any ongoing interactions or 
interventions with the subjects, but continues to meet the regulatory definition of 
“human subjects research” (for example, it involves the continued analysis of 
specimens or data for which the subject’s identity is readily identifiable to the 
investigator(s)), then it would be necessary for the investigator(s) to seek and 
obtain the legally effective informed consent of the now-adult subjects.6 
 
At the heart of OHRP’s recommendations is the concern that when pediatric research 
participants reach the age at which they can provide legal consent, they may not want to continue 
participating in research in which their parents enrolled them. Thus, seeking their consent when 
they become legal adults ostensibly respects ethical norms of respect for persons. Within the 
context of traditional pediatric clinical research trials, the framework suggested by OHRP 
mirrors established models for consent of minors that both recognize their unique vulnerabilities 
and seek to respect their emerging capacity to provide informed consent to participate in 
research.  
 
The recent regulatory changes to the Common Rule do not contain a provision clarifying 
the issue about obtaining consent from pediatric biobank participants once they reach the age at 
which they can provide legal consent.7 Thus, Subpart D of the Revised Common Rule remains 
unchanged with respect to the requirements for consent of pediatric participants and there has, as 
yet, been no indication that OHRP’s FAQs will be revised or supplemented. These regulations 
and guidelines have not kept pace with current biospecimen-related research, which involves 
large numbers of participants of a variety of ages, potentially long-term storage of their 
biospecimens and associated data, and a variety of initial consent approaches. Nor do they reflect 
the current understanding of the developing capacity of legal minors to consent to minimal risk 
medical research.  
 
 We believe that the consent guidance articulated in the FAQs is overly restrictive and 
could have the potential to exacerbate the already marked inequities in opportunities for pediatric 
research participants. This, in turn could result in less innovation in treatment and prevention of 
diseases in both pediatric and adult contexts.8 For example, as we become better at treating 
pediatric disease, research on stored biospecimens may help researchers understand and prevent 
long-term sequelae of pediatric disease. Additionally, the ability to use biospecimens obtained 
from children and adolescents after they become legal adults could provide key insights into the 
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prevention of serious adult conditions, such as diabetes or cardiovascular diseases.  
 
 As pediatric biobank research grows, additional guidance will be needed about whether 
researchers should always obtain consent from participants when they reach the legal age of 
majority. Biobanks struggle with a range of practical and ethical issues related to this issue.9 For 
biobanks that have a single collection of biospecimens but do not follow pediatric participants 
longitudinally, obtaining their consent after they reach the age of majority may not be feasible. 
Families relocate without providing forwarding addresses and tracking of hundreds or thousands 
of participants could be cost-prohibitive. Additionally, linkages with paper and electronic 
medical records vary in the extent to which identifiable information about participants is 
connected to individual biospecimens and made available to researchers.10  Brothers and 
colleagues suggest that researchers should consider prospectively developing plans to obtain 
consent from participants upon legal adulthood and that institutional review boards (IRBs) 
should be willing to grant “consent waivers” where attempts to recontact pediatric participants 
are not successful. Brothers argues these waivers should be granted even for identifiable 
pediatric biospecimens and associated data.11  
 
We endorse the approach Brothers and colleagues proposed and in this article outline a 
framework for the use of “anticipatory waivers of consent.” Our proposal is empirically rooted in 
research which has demonstrated that children and adolescents are often developmentally 
capable of meaningful deliberation about the risks and benefits of participation in research.12  
Accordingly, bright line legal concepts of majority or competency do not accurately capture the 
emerging capacity for autonomous decision-making of many pediatric research participants and 
unnecessarily complicate the issues about contacting participants at the age of majority to obtain 
consent for the continued or first use of their biospecimens that were obtained during childhood. 
We believe this proposal provides an ethically sound balance between the concern for potential 
exploitation of vulnerable populations (the impetus for Subpart D) and the need to conduct 
valuable research in the age of genomic medicine. 
 
 
Research with Biospecimens from Pediatric Participants 
 
Research with biospecimens from children and adolescents serves two primary purposes: to 
understand pediatric-specific diseases, such as many childhood cancers, which have no adult 
equivalent, and 2) to understand the long-term effects of the interaction between genetic and 
environmental exposures on adult disease and wellness.13 For example, adult survivors of 
pediatric cancer experience a high rate of secondary malignancies leading to increased 
morbidity.14 Longitudinal research with biospecimens might identify predictors of outcomes 
among adult survivors, which in turn could lead to more precise and effective administration of 
chemotherapy protocols in pediatric patients. 
 
 The scientific benefit of biobanking is largely owed to its aggregation of large quantities 
of biospecimens with an ever-increasing amount of health data that can be connected with those 
biospecimens. While clinical research prior to biobanking may have involved several hundred 
participants in a single study, as noted above, contemporary biorepositories contain considerably 
larger quantities of biospecimens. Indeed, 20% of biobanks now contain more than 100,000 
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biospecimens.15 Because biobanking is also distinct from other areas of clinical research in that 
there is often no defined study or even research question at the time the biospecimens are 
collected, obtaining informed consent at the time biospecimens are collected can be complicated. 
For example, individuals may be asked to consent to future unspecified research with their 
biospecimens and associated data. When adults contribute their biospecimens to a biobank, they 
are agreeing to accept the potential risks of harm from biospecimen-related research, which 
include harms from disclosure to others of genetic information derived from analysis of their 
biospecimens.16 Some might argue that children and adolescents are incapable of understanding 
these issues, as well as the fact that research with biospecimens generally will not provide a 
direct benefit to them. Rather, the benefit is “the possibility of accurate genetic diagnosis in the 
future”—arguably a group benefit.17 Taken together, these factors seem to require that some 
special consideration be given to the consent process for pediatric biobank participants. 
 
As noted earlier, Subpart D of federal research regulations, “Additional Protections for 
Children Involved as Subjects in Research” does not address the matter of obtaining consent 
from legal adults whose parents enrolled them in research when they were legal minors. Rather, 
it requires researchers to obtain, at the time of enrollment in research, “the assent of the children, 
when in the judgment of the IRB the children are capable of providing assent.”18 This 
determination can be based on “the ages, maturity, and psychological state of the children 
involved.”19 Along with the assent of the child, the IRB must determine that “adequate 
provisions are made for soliciting the permission of each child’s parents or guardian.”20 While 
our proposal for an anticipatory waiver of consent in the context of pediatric biobanking 
acknowledges concerns about children as vulnerable populations, it also seeks to respect the 
emerging capacity of some children and adolescents to understand and appreciate the risks and 
benefits of research participation. 
 
A Framework for Anticipatory Waivers of Consent 
 
The complexity of obtaining consent from pediatric biobank participants when they reach the age 
of legal majority turns on two key issues. The first is the variety and diversity of purposes and 
practices of individual biobanks, which makes them poorly suited to the framework of the 
Common Rule.21 The second is the role of “emerging capacity” that arises in pediatric medicine, 
and thus, pediatric research. Consequently, the approach to consent from pediatric biobank 
participants when they involve minors requires a two-tiered analysis: 1) define the nature of the 
research; and 2) identify the vulnerabilities implicated by the participants in a given pediatric 
study. 
 
 Leaving aside the legal and regulatory conceptions of consent for a moment, consent 
within the domain of pediatric research as it is understood from an ethical perspective is 
increasingly informed by an appreciation for the evolving developmental capacity of minors – 
particularly of adolescents – to consent to research. This evolving or emerging capacity is not 
adequately reflected in the legal concept of competency, which demands adherence to a bright-
line rule, such as reaching the age of majority. Work done by Kipnis examining pediatric 
vulnerabilities, however, best captures the unique nature of vulnerability as it relates to pediatric 
participants in research.   
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Kipnis’s concepts of incapacitational and juridic vulnerability are particularly salient to 
the issue of biobanking. Incapacitational vulnerability pertains to whether a particular research 
subject has the initial decisional capacity to deliberate about whether to participate in a proposed 
study.22 As Kipnis notes, decisional capacity is not necessarily tied to the age of legal majority.23 
Rather, significant research indicates that minors frequently develop the ability to adequately 
deliberate and weigh the risks and benefits of participating in medical research well before the 
age of legal majority. For example, a recent analysis of the decisional capacity of children 
relative to clinical research indicates that decisional capacity can be present in children as young 
as 9.6 years, and is probable in children by the age of 12.24 This finding is consistent with 
additional research demonstrating that age, family affluence, and health literacy correlate more 
strongly with decisional capacity than legal competency alone, with health literacy as the 
strongest predictor of whether an adolescent has the ability to meaningfully deliberate about 
participation in research.25 Consequently, several authors have already argued for the 
appropriateness of using standardized competence assessments in children that do not rise and 
fall on the child’s biological age alone.26 
 
 Similarly, the question of juridic vulnerability recognizes that minors are vulnerable to 
exploitation simply because of the “formal authority relationships that characterize many social 
structures.”27 One way to guard against the potential for exploitation is to include minors in the 
initial decision-making process to the extent they are capable of inclusion, and then to return 
decisional authority to them once the “formal authority relationship” has ended. However, the 
research noted above by Nelson, Hein, and others suggests that the investigators themselves may 
be in the best position to determine whether a specific vulnerability is actually undermining 
capacity for an individual participant.28 
 
 Because there is increasing evidence that many adolescents are developmentally capable 
of providing their consent at the initiation of minimal-risk research or when they are asked to 
provide their biospecimens for research, a rigid requirement to obtain consent from them when 
they reach the age of legal majority seems unnecessarily and overly protective to the detriment of 
important research. And as noted earlier, complying with such a requirement frequently will be 
impracticable since it would require tracking the dates when potentially thousands of biobank 
participants reach the age of majority and attempting to contact them, with likely inconsistent 
success in doing so. 
  
A better approach that is less disruptive, but still respects the autonomy of research 
participants, would involve the use of anticipatory waivers of consent. As a matter of practice, 
this will require researchers, at the time they submit a research protocol to the IRB, to request a 
waiver from having to obtain consent from pediatric biobank participants when they reach the 
age of majority. This anticipatory waiver of consent would only be available in accordance with 
the existing requirements for obtaining a waiver from an IRB of the regulatory consent 
requirement for human subjects research: the research involves no more than minimal risk; the 
waiver of consent will not adversely affect the rights and welfare of the research participants; the 
research cannot practicably be carried out without the waiver; and when appropriate, research 
participants will be provided with additional pertinent information after participation.29 We 
describe below three primary components of our proposed framework for an anticipatory waiver 
of consent.  
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Investigators should undertake a comprehensive initial permission-assent process. 
 
The parental permission and child assent requirements in Subpart D of the federal 
regulations recognize that many children can and should be involved in the consent process for   
enrolling in research, and that obtaining assent is appropriate depending on the ages and maturity 
of the child involved. As noted above, studies have shown that many children and adolescents 
are capable of understanding research and should be given the opportunity to actively participate 
in the consent process in which parental permission for enrollment is being sought.30 This 
includes potentially advising children and adolescents that enrolling in genomic research 
involves of a wide range of considerations, including the risk of loss of privacy, discrimination 
related to the findings of the research, and any conflicts of interest the researchers may have.31  
Investigators should also use this opportunity to explain to children, adolescents, and their 
parents that there is a possibility the researchers will not contact the participants when they 
become legal adults to obtain consent for continued or future research with their biospecimens. 
 
As it relates to assessing decisional capacity, given that research demonstrates the 
presence of decisional capacity in children by approximately the age of 12, investigators 
involved in minimal-risk research may rely on their assessment of the individual’s 
developmental level, health literacy, and age to determine whether she or he is capable of 
providing meaningful consent. Because there is variation in the age at which individual children 
and adolescents are developmentally capable of engaging in meaningful deliberation regarding 
research, investigators seeking from the IRB an anticipatory waiver of consent could agree to use 
a brief capacity assessment tool during the consent process. For example, the tool known as the 
University of California, San Diego Brief Assessment of Capacity to Consent, has been shown to 
provide an accurate picture of a potential participant’s ability to consent to clinical research and 
takes less than five minutes to implement.32     
 
Admittedly, this latitude at the research level may make some uncomfortable. However, 
it is important to keep in mind that “minimal risk” as specifically defined in the Common Rule 
does not mean risk-free. Instead, minimal risk has been defined to mean that “the probability and 
magnitude of harm or discomfort anticipated in the research are not greater in and of themselves 
than those ordinarily encountered in daily life or during the performance of routine physical or 
psychological examinations or tests.”33 The process of consenting to a minimal risk study is 
significantly less involved and less consequential than the process of, for example, enrolling in a 
cancer treatment study in which a participant is randomized to an experimental medication that 
has known, and sometimes, unknown immediate and long term effects. Accordingly, reliance on 
ethical concepts of emerging capacity is more appropriate than reliance on legal concepts of 
competency in the minimal risk research context.   
 
IRBs should grant waivers at the time they approve research protocols. 
 
One of the complicating factors of biobanking research is that when biospecimens are 
collected for future unspecified research, individuals will not know in what types of studies their 
biospecimens will be used. This fact alone, however, should not be dispositive of the issue of 
anticipatory waivers of consent. To the extent biobanks have adequate policies requiring 
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developmentally appropriate consent procedures, including informing participants of the nuances 
of biobanking research (i.e., that research is conducted over a long period of time, that a study 
may not be fully articulated at the time biospecimens are collected, and that unless the study 
poses greater than minimal risk, pediatric participants will not be contacted for consent with they 
become legal adults), investigators should request and be granted an anticipatory waiver of 
consent. 
 
We suggest that IRBs could grant an anticipatory waiver of consent when several 
conditions are met: 1) the waiver is granted when children 12 years and older will be asked to 
provide their biospecimens for a biobank or specific study; 2) during the informed consent 
process children over age 12 demonstrate adequate decisional capacity to assent to research 
participation; 3) children and their parents are informed that the child’s biospecimens might be 
used for future unspecified research, including research in which the participant’s identity is 
known; 4) children and their parents are informed that when the participant reaches the age of 
legal majority the participant can opt out of research with their biospecimens and information 
about  how to opt out is provided; 5) for research with their biospecimens after they reach the age 
of majority, researchers will use participants’ last known address to contact them at least three 
times to obtain their consent; and 6) if researchers are unable to find participants when they 
research the age of majority then research with their biospecimens will go forward in accordance 
with an IRB-approved anticipatory waiver of consent. 
 
 The criteria above are not over-broad, as would be the case if the waiver of consent was 
requested for pediatric biobank participants of all ages. Nor do they impose an overly 
burdensome consent process for every biobank participant who reaches the legal age of majority 
as would be the case if IRBs followed OHRP’s FAQs guidance. 
  
Conclusions 
 
One potential concern about the framework for anticipatory waivers of consent is the extent to 
which granting such waivers may undermine the public trust in biobanks or ignore individual’s 
preferences for control over the use of their biospecimens and associated data, which could lead 
to parents being less likely to enroll their children in important research. The findings of one 
study involving adolescent patients in oncology, cardiology, and orthopedic clinics found that 
50% the adolescents and 64% of their parents felt that consent at the age of legal majority for use 
of pediatric samples was either “important” or “very important.” However, when asked whether 
biospecimens should still be used if attempts to obtain such consent were unsuccessful, more 
than half of the adolescents and their parents said yes.34 
  
 In another study, 60% of adult (18-34 years old) cancer survivors whose biospecimens 
had been obtained during their childhood thought they should be asked for consent when they 
became legal adults, and all of the study participants gave permission for their biospecimens to 
remain in the biobank.35 These findings suggest that pediatric biobank participants are willing for 
their biospecimens to be used for research after they become legal adults, but that they still want 
to be asked for permission for such use. 
 
 Pediatric biobanking research is important to the continued advancement of medical 
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knowledge and technology. However, it presents challenges with respect to whether participants 
should be contacted for their consent when they reach the age of legal majority. In our view, the 
restrictive standard articulated in OHRP’s FAQs fails to acknowledge the developing capacity of 
pediatric research participants to consent to minimal risk research and potentially imposes 
unduly burdensome requirements on investigators, threatening important research. Our 
recommendations regarding the use of anticipatory waivers of consent are  consistent with 
previous suggestions that investigators should anticipate challenges and develop prospective 
plans for addressing consent issue when pediatric biobank participants become legal adults.36  We 
acknowledge that our proposed framework means that IRBs are effectively being asked to be 
more accommodating in permitting researchers to continue or begin using biospecimens from 
pediatric participants without their consent when they become legal adults. As such, investigators 
should provide assurances to the IRB that they will 1) engage in detailed and appropriate 
informed consent processes at the front end of research with legal minors who are 
developmentally capable of engaging in the informed consent process, and 2) make efforts to 
contact participants when they reach the legal age of majority when contact information is 
available. We believe our framework is a balanced approach that promotes important research as 
well as the interests of biobank participants.  
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